Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR STEPHANE COHEN
62 AVENUE FRANCOIS MITTERRAND, 94000 CRETEIL
QARE SANTE
10 R DE PENTHIEVRE, 75008 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
RMD open · 2023
Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD). Methods Safety data from clinical trials of upadacitinib 15 mg and upadacitinib 30 mg (AD only) for treating RA, PsA, AS and AD as of 30 June 2021 were analysed; some RA and PsA studies included adalimumab and methotrexate as active comparators. Treatment-emergent adverse events (TEAEs) were presented by disease as exposure-adjusted event rates per 100 patient years (E/100 PY). Results The analysis included 6991 patients (RA, n=3209; PsA, n=907; AS, n=182; AD, n=2693) who received at least one dose of upadacitinib, representing 15 425 PY of exposure (maximum duration 2.75–5.45 years) across diseases. Rates (E/100 PY) of any TEAE (205.5–278.1) and TEAE leading to discontinuation (4.5–5.4) were similar across diseases; serious TEAEs were numerically higher in patients with RA and PsA. Rates of herpes zoster (1.6–3.6), non-melanoma skin cancer (0–0.8) and elevations in creatine phosphokinase levels (4.4–7.9) were higher with upadacitinib than with active comparators in the RA and PsA populations. Deaths (0–0.8), serious infections (0–3.9), major adverse cardiovascular events (0–0.4), venous thromboembolism (<0.1–0.4) and malignancies (0.3–1.4) were observed, with rates generally lowest in AS and AD. Increased rates of acne were observed in patients with AD only. Conclusions Findings from this analysis demonstrate that upadacitinib is generally well tolerated with observed differences in safety profiles likely reflective of varying patient characteristics across RA, PsA, AS and AD populations. Trial registration numbers NCT02675426, NCT02706951, NCT02706847, NCT02629159, NCT02706873, NCT03086343, NCT03104374, NCT03104400, NCT03178487, NCT03569293, NCT03568318 and NCT03607422.
Journal of medical Internet research · 2023
Background Chronic shoulder pain (CSP) is a common condition with various etiologies, including rotator cuff disorders, adhesive capsulitis, shoulder instability, and shoulder arthritis. It is associated with substantial disability and psychological distress, resulting in poor productivity and quality of life. Physical therapy constitutes the mainstay treatment for CSP, but several barriers exist in accessing care. In recent years, telerehabilitation has gained momentum as a potential solution to overcome such barriers. It has shown numerous benefits, including improving access and convenience, promoting patient adherence, and reducing costs. However, to date, no previous randomized controlled trial has compared fully remote digital physical therapy to in-person rehabilitation for nonoperative CSP. Objective The aim of this study is to compare clinical outcomes between digital physical therapy and conventional in-person physical therapy in patients with CSP. Methods We conducted a single-center, parallel-group, randomized controlled trial involving 82 patients with CSP referred for outpatient physical therapy. Participants were randomized into digital or conventional physical therapy (8-week interventions). The digital intervention consisted of home exercise, education, and cognitive behavioral therapy (CBT), using a device with movement digitalization for biofeedback and asynchronous physical therapist monitoring through a cloud-based portal. The conventional group received in-person physical therapy, including exercises, manual therapy, education, and CBT. The primary outcome was the change (baseline to 8 weeks) in function and symptoms using the short-form of Disabilities of the Arm, Shoulder, and Hand questionnaire. Secondary outcome measures included self-reported pain, surgery intent, analgesic intake, mental health, engagement, and satisfaction. All questionnaires were delivered electronically. Results A total of 90 participants were randomized into digital or conventional physical therapy, with 82 receiving the allocated intervention. Both groups experienced significant improvements in function measured by the short-form of the Disabilities of the Arm, Shoulder, and Hand questionnaire, with no differences between groups (–1.8, 95% CI –13.5 to 9.8; P=.75). For secondary outcomes, no differences were observed in surgery intent, analgesic intake, and mental health or worst pain. Higher reductions were observed in average and least pain in the conventional group, which, given the small effect sizes (least pain 0.15 and average pain 0.16), are unlikely to be clinically meaningful. High adherence and satisfaction were observed in both groups, with no adverse events. Conclusions This study shows that fully remote digital programs can be viable care delivery models for CSP given their scalability and effectiveness, assessed through comparison with high-dosage in-person rehabilitation. Trial Registration ClinicalTrials.gov (NCT04636528); https://clinicaltrials.gov/study/NCT04636528
Arthritis & rheumatology (Hoboken, N.J.) · 2023
ObjectivePreliminary evidence suggests that vagus nerve stimulation (VNS) may have some benefit in patients with rheumatoid arthritis (RA); however, prior studies have been small and/or uncontrolled; this study aimed to address that gap.MethodsThis randomized, double‐blind, sham‐controlled trial enrolled patients aged 18 to 75 years with active RA who had failed conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) and were naïve to biologic and/or targeted synthetic DMARDs. All patients received an auricular vagus nerve stimulator and were randomized 1:1 to active stimulation or sham. The primary endpoint was the proportion of patients achieving 20% improvement in American College of Rheumatology criteria (ACR20) at week 12. Secondary endpoints included mean changes in disease activity score of 28 joints with C‐reactive protein (DAS28‐CRP) and Health Assessment Questionnaire‐Disability Index (HAQ‐DI).ResultsA total of 113 patients (mean age 54 years; 82% female) enrolled, and 101 patients (89.4%) completed week 12. ACR20 response at week 12 was 25.0% for active stimulation versus 26.9% for sham (difference vs. sham, −1.9; 95% CI, −18.8, 14.9, P = 0.823). The least square mean ± SE change in DAS28‐CRP was −0.95 ± 0.16 for active stimulation and −0.66 ± 0.16 for sham (P = 0.201); in HAQ‐DI it was −0.19 ± 0.06 for active stimulation and −0.02 ± 0.06 for sham (P = 0.044). Adverse events occurred in 17 patients (15%); all were mild or moderate.ConclusionAuricular VNS did not meaningfully improve RA disease activity. If VNS with other modalities is pursued in the future for the treatment of RA, larger, controlled studies will be needed to understand its utility.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Current opinion in rheumatology · 2026 · Journal Article
Cohen S, Winthrop KL
Arthritis & rheumatology (Hoboken, N.J.) · 2026 · Journal Article
van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, et al.
Journal inconnu · 2026 · Study Guide
Orhurhu VJ, Roberts JS, Ly NK, Cohen SP
Interventional pain medicine · 2025 · Editorial
Warner NS, Cohen SP
Pain medicine (Malden, Mass.) · 2025 · Journal Article
Ravyts SG, Fleagle TR, Staguhn E, Scharfstein D, et al.
Annals of the rheumatic diseases · 2025 · Journal Article
van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, et al.
The journal of knee surgery · 2025 · Journal Article
Cohen SB, Hajnik C, Loren GJ, Akhavan S, et al.
Journal of the American Geriatrics Society · 2025 · Journal Article
Ravi M, Honigman J, Gibbons S, Cohen S, et al.
Cancer immunology, immunotherapy : CII · 2025 · Journal Article
Ploch M, Zhao S, Wei L, Englert JA, et al.
Pain practice : the official journal of World Institute of Pain · 2025 · Journal Article
Vanneste T, Belba A, Oei GTML, Emans P, et al.
Joint bone spine · 2024 · Review
Chen Y, Nelson AM, Cohen SP
Kidney medicine · 2024 · Journal Article
Kwon AG, Sawaf H, Portalatin G, Shettigar S, et al.
Regional anesthesia and pain medicine · 2024 · Journal Article
Chen Y, Wang E, Sites BD, Cohen SP
Arthroscopy, sports medicine, and rehabilitation · 2024 · Journal Article
Perez AR, Coladonato C, Hanna AJ, Sabitsky M, et al.
Clinical and experimental rheumatology · 2024 · Journal Article
Cohen SP, Wodarcyk AJ, Wong A, Patterson KC, et al.
Interventional pain medicine · 2024 · Editorial
Cohen SP, Gerdesmeyer L, McCormick ZL
Annals of gastroenterology · 2024 · Journal Article
Mari A, Cohen S, Cohen DL, Khoury T, et al.
Open access rheumatology : research and reviews · 2023 · Journal Article
Cohen SB, Leach MZ
Regional anesthesia and pain medicine · 2023 · Editorial
Cohen SP, Mishra P, Wallace M, Sellers A, et al.
Rheumatology and therapy · 2023 · Journal Article
Cohen S, Curtis JR, Mellors T, Zhang L, et al.
Arthroplasty today · 2022 · Journal Article
Cohen SA, Brophy RH, Chen AF, Roberts KC, et al.
Immunotherapy · 2022 · Research Support, Non-U.S. Gov't
Cohen SB, Lee EC
Video journal of sports medicine · 2022 · Journal Article
Johnson EE, Campbell M, Cohen SB
Orthopaedic journal of sports medicine · 2022 · Journal Article
Erickson BJ, Chalmers PN, D'Angelo J, Ma K, et al.
Regional anesthesia and pain medicine · 2025 · Journal Article
Sawang S, Kimpee P, Itthichaikulthol W, Tontisirin N, et al.
Seminars in arthritis and rheumatism · 2025 · Journal Article
Allen HM, Holena MM, Allen LE, Zhao S, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2023 · Randomized Controlled Trial
Baker MC, Kavanagh S, Cohen S, Matsumoto AK, et al.
RMD open · 2025 · Journal Article
Smolen JS, Emery P, Rigby W, Tanaka Y, et al.
Rheumatology and therapy · 2024 · Published Erratum
Burmester GR, Coates LC, Cohen SB, Tanaka Y, et al.
Rheumatology and therapy · 2023 · Journal Article
Burmester GR, Coates LC, Cohen SB, Tanaka Y, et al.
Rheumatology and therapy · 2025 · Journal Article
Jin R, Haughton JM, Goddard EJ, Courmier D, et al.
Expert opinion on biological therapy · 2025 · Journal Article
Cohen S, Bender S, Shaberman A, Vinisko R, et al.
Expert opinion on biological therapy · 2025 · Journal Article
Cohen S, Bender S, Shaberman A, Vinisko R, et al.
Lupus · 2026 · Journal Article
Vyas A, Cohen S, Eisenhower C
Scientific reports · 2025 · Journal Article
Vyas A, Cohen S, Eisenhower C
Arthritis research & therapy · 2024 · Journal Article
Cohen S, Beebe JS, Chindalore V, Guan S, et al.
RMD open · 2025 · Journal Article
Smolen JS, Emery P, Rigby W, Tanaka Y, et al.
Clinical therapeutics · 2022 · Journal Article
Cohen SB, Haraoui B, Curtis JR, Smith TW, et al.
Pediatric pulmonology · 2024 · Journal Article
Cohen SP, Eisner M, Fussner LA, Krivchenia K
Journal of pediatric gastroenterology and nutrition · 2024 · Journal Article
Anafy A, Mirkin Y, Galai T, Ben-Tov A, et al.
Current opinion in rheumatology · 2023 · Review
Cohen S, Reddy V
ACR open rheumatology · 2022 · Journal Article
Abuqayyas L, Cheng LE, Teixeira Dos Santos M, Sullivan BA, et al.
Regional anesthesia and pain medicine · 2025 · Journal Article
Sawang S, Kimpee P, Itthichaikulthol W, Tontisirin N, et al.
Seminars in arthritis and rheumatism · 2025 · Journal Article
Allen HM, Holena MM, Allen LE, Zhao S, et al.
Journal of medical Internet research · 2023 · Randomized Controlled Trial
Pak SS, Janela D, Freitas N, Costa F, et al.
Healthcare (Basel, Switzerland) · 2022 · Journal Article
Janela D, Costa F, Areias AC, Molinos M, et al.
Journal of translational autoimmunity · 2023 · Journal Article
Shapiro J, Getz B, Cohen SB, Jenudi Y, et al.
The Journal of rheumatology · 2025 · Editorial
Cohen SB, Saag KG
HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025 · Journal Article
Cohen SR, Wesson J, Canikyan S, Tiryaki T
The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association · 2025 · Journal Article
Cohen SM, Morrison KA, Nguyen TT, Dedeoglu F, et al.
Journal of medical Internet research · 2023 · Randomized Controlled Trial
Pak SS, Janela D, Freitas N, Costa F, et al.
Regional anesthesia and pain medicine · 2022 · Journal Article
Malaithong W, Tontisirin N, Seangrung R, Wongsak S, et al.
ACR open rheumatology · 2022 · Journal Article
Abuqayyas L, Cheng LE, Teixeira Dos Santos M, Sullivan BA, et al.
Rheumatology and therapy · 2023 · Journal Article
Winthrop KL, Yndestad A, Henrohn D, Danese S, et al.
RMD open · 2023 · Clinical Trial
Burmester GR, Cohen SB, Winthrop KL, Nash P, et al.
Clinical therapeutics · 2022 · Journal Article
Cohen SB, Haraoui B, Curtis JR, Smith TW, et al.